RxDoctor Payments Data

Anatole Hounnou, DO

Hospitalist · Kernersville, NCNPI 1922399930

Payments from drug & device makers

$1,960in general payments, 2019–2025

Across 37 payments — averaging $52.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$118
  • Novo Nordisk$101
  • Boston Scientific$62
  • VBI Vaccine (delaware) Inc.$45
  • Medtronic$27
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$1,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca23$1,566
Johnson & Johnson2$118
Novo Nordisk5$101
Boston Scientific1$62
VBI Vaccine (delaware) Inc.3$45
Medtronic1$27
Merck1$26
Novartis1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,960 in reported general payments places this provider in the 80th percentile of 879 hospitalist providers in North Carolina.

See all hospitalist providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,404
Medicare patients
167
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$14,528
OzempicSemaglutide16$13,985
JanuviaSitagliptin Phosphate12$10,540
Albuterol Sulfate HfaAlbuterol Sulfate74$2,270
Metoprolol Succinate54$1,121
Atorvastatin Calcium117$1,019
Amlodipine Besylate138$1,010
Omeprazole78$758
Losartan Potassium43$628
Diclofenac Sodium19$595
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide30$575
Levothyroxine Sodium25$376
Mirtazapine18$340
Enalapril Maleate37$336
Gabapentin26$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,566$14,52816 claims
Novo NordiskOzempic$101$13,98516 claims
MerckJanuvia$26$10,54012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 879 hospitalist providers in North Carolina.

Other hospitalist in Kernersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →